Results 231 to 240 of about 412,223 (311)

The role of the National Health Insurance Scheme in strengthening delivery of health services among the elderly at district level in Zambia: a qualitative case study. [PDF]

BMC Public Health
Sakala L, Zyambo C, Chavula MP.
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Risk Stratification of Long-Term Mortality in Infants with Congenital Diaphragmatic Hernia Using the National Health Insurance Service (NHIS) Data. [PDF]

Children (Basel)
Han HJ, Suh MJ, Choi IY, Park JS, Kim HS, Yang HJ, Suh DI, Lee E, Kim KH.   +8 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

National Health Insurance exposed.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2010
openaire   +2 more sources

Safety of herbal medicine decoction for facial palsy: Coarsened exact matching analysis of the national health insurance database. [PDF]

Integr Med Res
Kim Y, Yoon NH, Jang S, Bae K, Moon W, Park M, Kim S.   +6 more
europepmc   +1 more source

Correction to "Implementation of the Hospitalist System and In-Hospital Mortality Among Patients With Cancer: Using the National Health Insurance Cohort Data". [PDF]

Cancer Med
europepmc   +1 more source

Willingness and perceived ability to pay for Uganda's proposed national health insurance scheme among informal sector workers in Iganga and Mayuge districts, Uganda: A contingent valuation method. [PDF]

PLOS Glob Public Health
Namuhani N, Kisakye AN, Kiwanuka SN.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source